T
Tae You Kim
Researcher at Seoul National University Hospital
Publications - 21
Citations - 6207
Tae You Kim is an academic researcher from Seoul National University Hospital. The author has contributed to research in topics: Chemoradiotherapy & Breast cancer. The author has an hindex of 13, co-authored 21 publications receiving 4677 citations. Previous affiliations of Tae You Kim include New Generation University College & Seoul National University.
Papers
More filters
Journal ArticleDOI
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry,Bruno Sangro,Thomas Yau,Todd S. Crocenzi,Masatoshi Kudo,Chiun Hsu,Tae You Kim,Su Pin Choo,Jörg Trojan,Theodore H. Welling,Tim Meyer,Yoon-Koo Kang,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Hao Tang,Homa Dastani,Ignacio Melero +20 more
TL;DR: Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma, and safety and tolerability for the escalation phase and objective response rate were primary endpoints.
Journal ArticleDOI
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke,Kei Muro,Eric Van Cutsem,Sang Cheul Oh,György Bodoky,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Oleg Lipatov,Tae You Kim,David Cunningham,Philippe Rougier,Yoshito Komatsu,Jaffer A. Ajani,Michael Emig,Roberto Carlesi,David Ferry,Kumari Chandrawansa,Jonathan D. Schwartz,Atsushi Ohtsu +19 more
TL;DR: The combination of ramucirumab with pac litaxel significantly increases overall survival compared with placebo plus paclitaxel, and could be regarded as a new standard second-line treatment for patients with advanced gastric cancer.
Journal ArticleDOI
Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial.
Seung-Yong Jeong,Seung-Yong Jeong,Ji Won Park,Ji Won Park,Byung-Ho Nam,Sohee Kim,Sung Bum Kang,Seok Byung Lim,Hyo Seong Choi,Duck Woo Kim,Hee Jin Chang,Dae Yong Kim,Kyung Hae Jung,Tae You Kim,Gyeong Hoon Kang,Eui Kyu Chie,Sun-Young Kim,Dae Kyung Sohn,Dae-Hyun Kim,Jae Sung Kim,Hye Seung Lee,Jee Hyun Kim,Jae Hwan Oh +22 more
TL;DR: The results show that laparoscopic resection for locally advanced rectal cancer after preoperative chemoradiotherapy provides similar outcomes for disease-free survival as open resection, thus justifying its use.
Journal ArticleDOI
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial
Yong Sang Hong,Byung-Ho Nam,Kyu Pyo Kim,Jeong Eun Kim,Seong Joon Park,Young Suk Park,Joon Oh Park,Sun-Young Kim,Tae You Kim,Jee Hyun Kim,Joong Bae Ahn,Seok Byung Lim,Chang Sik Yu,Jin Cheon Kim,Seong Hyeon Yun,Jong Hoon Kim,Jin-Hong Park,Hee Chul Park,Kyung Hae Jung,Tae Won Kim +19 more
TL;DR: This open-label, multicentre, phase 2, randomised trial aimed to compare the efficacy and safety of adjuvant fluorouracil and leucovorin with that of FOLFOX in patients with locally advanced rectal cancer after preoperative chemoradiotherapy.
Journal ArticleDOI
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
Thomas Yau,Chiun Hsu,Tae You Kim,Su Pin Choo,Yoon-Koo Kang,Ming-Mo Hou,Kazushi Numata,Winnie Yeo,Akhil Chopra,Masafumi Ikeda,Ryoko Kuromatsu,Michihisa Moriguchi,Yee Chao,Huanyu Zhao,Jeffrey Anderson,Christine Dela Cruz,Masatoshi Kudo +16 more
TL;DR: The CheckMate 040 study as mentioned in this paper evaluated the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma who were refractory to previous sorafenib treatment or chemotherapy.